AU
UK
CA
NZ
IND
US
Company Overview
Company Overview
The Fragmentation Problem in Pharma Engagement
A Strategic Pivot Toward the Sun Belt
A regulatory inflection for ImmunityBio
A price transparency blitz in a $600bn U.S. generics market
Merck & Co. (NYSE: MRK) and Kelun-Biotech’s experimental antibody–drug conjugate sacituzumab tirumotecan (sac-TMT) has become the first globally successful phase 3 therapy in endometrial cancer, a malignancy where new systemicOptionsremain scarce. The TroFuse-005 study met both co-primary endpoints—overall survival (OS) and progression-free survival (PFS)—according …
A historic green light for Enhertu
A landmark licensing pact to widen access to influenza treatment
Please wait processing your request...